XML 15 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 17, 2025
Jun. 28, 2024
Document Information [Line Items]      
Entity Central Index Key 0001488039    
Entity Registrant Name ATOSSA THERAPEUTICS, INC.    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 001-35610    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 26-4753208    
Entity Address, Address Line One 10202 Fifth Avenue NE    
Entity Address, Address Line Two Suite 200    
Entity Address, City or Town Seattle    
Entity Address, State or Province WA    
Entity Address, Postal Zip Code 98125    
City Area Code 206    
Local Phone Number 588-0256    
Title of 12(b) Security Common Stock, $0.18 par value    
Trading Symbol ATOS    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 149,586,095
Entity Common Stock, Shares Outstanding   129,170,004  
Auditor Firm ID 42    
Auditor Name EY    
Auditor Location Seattle, Washington    
Document Financial Statement Error Correction [Flag] false    
Documents Incorporated by Reference [Text Block]

Portions of the registrant’s Definitive Proxy Statement for the registrant’s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2024.

    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Atossa Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.